Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (3)
P 4 (2)

Trial Status

Recruiting3
Not Yet Recruiting2
Unknown1

Clinical Trials (6)

Showing 6 of 6 trials
NCT07417215Phase 4Not Yet Recruiting

The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF

NCT07192341Not ApplicableRecruitingPrimary

Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction

NCT06900803Not ApplicableNot Yet Recruiting

Evaluating Dashboard-Integrated Pharmacist-Led Education on Improving Sacubitril/Valsartan Adherence in Heart Failure (PharmD ASSIST HFrEF)

NCT05465031Phase 4Recruiting

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

NCT05498675RecruitingPrimary

Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

NCT03791723Not ApplicableUnknown

Effect of ARNI in Patients With Persistent AF and Enlarged Left Atrium After Catheter Ablation

Showing all 6 trials

Research Network

Activity Timeline